Document is current
Any future updates will be listed below
-
Authors
Smeijer, J. David https://orcid.org/0000-0003-1725-9927
de Vries, Sieta T. https://orcid.org/0000-0001-6090-2434
Kohan, Donald E. https://orcid.org/0000-0002-3981-2941
Hou, Fan Fan https://orcid.org/0000-0003-3117-7418
Heerspink, Hiddo J. L. https://orcid.org/0000-0002-3126-3730
-
Funding
Funding for this research was provided by:
HORIZON Research and Innovation Actions (101095146)
Innovative Medicines Initiative (115974)
- License Information
-
More Information
Article History
Received: 11 July 2024
Accepted: 9 October 2024
First Online: 11 December 2024
Acknowledgements
: We thank all participants in the SONAR trial.
: The data analysed for the current study are not publicly available due to confidential patient information and are subject to contractual agreements with the original trial sponsor. However, these data are available from the corresponding author upon reasonable request, pending approval from the relevant parties and in accordance with applicable data protection regulations.
: This study has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement no. 115974 (BEAt-DKD). This project has also received funding from European Union’s HORIZON Research and Innovation Actions (HORIZON-HLTH-2022-TOOL-11-01 - Tools and technologies for a healthy society) undertaking under grant agreement no. 101095146. This project is funded by the European Union. The views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.
: DEK is a consultant for Asahi-Kasei, AstraZeneca, Novartis and Travere Therapeutics. FFH serves as the national leading investigator of China for the ALIGN study. HJLH has received grant funding and honoraria for consultancy as a member of the steering committee of the DAPA-CKD trial paid to his institution from AstraZeneca, research grants paid to his employer from AstraZeneca, Boehringer Ingelheim, Janssen and Novo Nordisk for clinical trials, consulting fees paid to his employer from AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli-Lilly, Gilead, Janssen, Novartis, Novo Nordisk and Travere Therapeutics, and honoraria for lectures from AstraZeneca, Bayer and Novo Nordisk. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.
: JDS and HJLH conceived and designed the study. JDS, with support from HJLH, analysed the data and developed the code. All authors contributed to the writing of the article, provided support for the analysis and interpretation of results, critically revised the article and approved the final article. JDS and HJLH are the guarantors of this work.
Free to read: This content has been made available to all.
